Angiogenesis inhibitors, such as epidermal growth factor receptor (EGFR) inhibitors, have been used to limit tumor growth;7 however, traditional angiogenesis inhibitors are not ideal in solid tumor treatment, which suggests that there may be another relatively independent microvascular system involved in tumor blood supply. The gene discussed is EGFR; the disease is neoplasm.